Stock Taper
Biomea Fusion, Inc. is a biopharmaceutical company founded in 2017 in Redwood City, CA, developing covalent small molecule drugs like BMF-219 to treat genetically defined cancers and metabolic diseases.

Biomea Fusion is a clinical-stage company developing oral medications for diabetes and obesity, including Icovamenib to regenerate insulin cells and BMF-650, a GLP-1 receptor agonist.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
ALXO | $2.00 | COMPARE |
IMUX | $15.40 | COMPARE |
STRO | $20.45 | COMPARE |
UNCY | $5.26 | COMPARE |
CBUS | $1.65 | COMPARE |
GUTS | $0.66 | COMPARE |
CAMP | $4.15 | COMPARE |
PMVP | $1.22 | COMPARE |